Benedikt Simon1, Harald Rubey1, Andreas Treipl2, Martin Gromann2, Boris Hemedi3, Sonja Zehetmayer4, Bernhard Kirsch2. 1. Mistelbach-Gänserndorf State Clinic, Institute for Medical-Chemical Laboratory Diagnostics, Austria. 2. Mistelbach-Gänserndorf State Clinic, Department for Internal Medicine III-Nephrology and Diabetology, Austria. 3. Hainburg State Clinic, Department for Internal Medicine, Austria. 4. MedUni Wien, Center for Medical Statistics, Informatics and Intelligent Systems (Institute of Medical Statistics), Austria.
Abstract
BACKGROUND: Haemodialysis (HD) patients are exposed to a high risk due to the SARS-CoV-2 pandemic. They are prone to acquiring the infection and are threatened by high mortality rates in case of infection. However, HD patients were not included in the efficacy trials of the SARS-CoV-2 vaccines. Such efficacy data would have been critical because HD patients show decreased responses against various other vaccines and this could translate to the SARS-CoV-2 vaccines as well. METHODS: We conducted a prospective cohort study that contained a group of 81 HD patients and 80 healthy controls. All of them had been vaccinated with the BioNTech/Pfizer mRNA vaccine (two doses, as per the manufacturer's recommendation). The anti-SARS-CoV-2 S antibody response was measured for all participants 21 days after the second dose. The groups were compared using univariate quantile regressions and a multivariate analysis. The adverse events (AEs) of the vaccination were assessed via a questionnaire. Finally, a correlation between the HBs-Antibody response and the SARS-CoV-2 antibody response in the HD patients was established. RESULTS: The HD patients had significantly lower Anti-SARS-CoV-2 S antibody titres than the control patients 21 days after vaccination (median was 171 U/ml for dialysis patients and 2,500 U/ml for the controls). Further, the HD group presented less AEs than the control group. No correlation was found between the antibody response to previous Hepatitis B vaccination and that of the SARS-CoV-2 vaccine. CONCLUSIONS: HD patients present highly diminished SARS-CoV-2 S antibody titres compared to a cohort of controls. Therefore, they could be much less protected by SARS-CoV-2 mRNA vaccinations than expected. Further studies to test alternative vaccination schemes should be considered.
BACKGROUND: Haemodialysis (HD) patients are exposed to a high risk due to the SARS-CoV-2 pandemic. They are prone to acquiring the infection and are threatened by high mortality rates in case of infection. However, HDpatients were not included in the efficacy trials of the SARS-CoV-2 vaccines. Such efficacy data would have been critical because HDpatients show decreased responses against various other vaccines and this could translate to the SARS-CoV-2 vaccines as well. METHODS: We conducted a prospective cohort study that contained a group of 81 HDpatients and 80 healthy controls. All of them had been vaccinated with the BioNTech/Pfizer mRNA vaccine (two doses, as per the manufacturer's recommendation). The anti-SARS-CoV-2 S antibody response was measured for all participants 21 days after the second dose. The groups were compared using univariate quantile regressions and a multivariate analysis. The adverse events (AEs) of the vaccination were assessed via a questionnaire. Finally, a correlation between the HBs-Antibody response and the SARS-CoV-2 antibody response in the HDpatients was established. RESULTS: The HDpatients had significantly lower Anti-SARS-CoV-2 S antibody titres than the control patients 21 days after vaccination (median was 171 U/ml for dialysis patients and 2,500 U/ml for the controls). Further, the HD group presented less AEs than the control group. No correlation was found between the antibody response to previous Hepatitis B vaccination and that of the SARS-CoV-2 vaccine. CONCLUSIONS:HDpatients present highly diminished SARS-CoV-2 S antibody titres compared to a cohort of controls. Therefore, they could be much less protected by SARS-CoV-2 mRNA vaccinations than expected. Further studies to test alternative vaccination schemes should be considered.
Authors: Ilona Cieślak; Magdalena Kwapisz; Olga Tronina; Joanna Gotlib; Wojciech Lisik; Dariusz Wasiak; Marta Hreńczuk; Mansur Rahnama; Piotr Małkowski Journal: Ann Transplant Date: 2022-09-16 Impact factor: 1.479
Authors: Matthew J Oliver; Doneal Thomas; Shabnam Balamchi; Jane Ip; Kyla Naylor; Stephanie N Dixon; Eric McArthur; Jeff Kwong; Jeffrey Perl; Mohammad Atiquzzaman; Joel Singer; Angie Yeung; Michelle Hladunewich; Kevin Yau; Amit X Garg; Jerome A Leis; Adeera Levin; Mel Krajden; Peter G Blake Journal: J Am Soc Nephrol Date: 2022-03-09 Impact factor: 14.978
Authors: Jens Van Praet; Marijke Reynders; Dirk De Bacquer; Liesbeth Viaene; Melanie K Schoutteten; Rogier Caluwé; Peter Doubel; Line Heylen; Annelies V De Bel; Bruno Van Vlem; Deborah Steensels; An S De Vriese Journal: J Am Soc Nephrol Date: 2021-09-29 Impact factor: 10.121
Authors: Edward J Carr; Andreas Kronbichler; Matthew Graham-Brown; Graham Abra; Christos Argyropoulos; Lorraine Harper; Edgar V Lerma; Rita S Suri; Joel Topf; Michelle Willicombe; Swapnil Hiremath Journal: Kidney Int Rep Date: 2021-07-06
Authors: Eva Schrezenmeier; Leon Bergfeld; David Hillus; Joerg-Detlev Lippert; Ulrike Weber; Pinkus Tober-Lau; Irmgard Landgraf; Tatjana Schwarz; Kai Kappert; Ana-Luisa Stefanski; Arne Sattler; Katja Kotsch; Thomas Dörner; Leif Erik Sander; Klemens Budde; Fabian Halleck; Florian Kurth; Victor Max Corman; Mira Choi Journal: Front Immunol Date: 2021-06-30 Impact factor: 7.561
Authors: Simone Cosima Boedecker-Lips; Anja Lautem; Stefan Runkel; Pascal Klimpke; Daniel Kraus; Philipp Keil; Stefan Holtz; Vanessa Tomalla; Paul Marczynski; Christian Benedikt Boedecker; Peter Robert Galle; Martina Koch; Julia Weinmann-Menke Journal: Pathogens Date: 2022-01-05